| Literature DB >> 34741111 |
Jiwei Zhong1, Haidan Wang2, Yun Zhuang3, Qun Shen4.
Abstract
Cryptotanshinone (CT) is an extract from the traditional Chinese medicine Salvia miltiorrhiza, which inhibits the growth of methicillin-resistant Staphylococcus aureus (MRSA) in vitro. This study aims to determine the antibacterial mechanisms of CT by integrating bioinformatics analysis and microbiology assay. The microarray data of GSE13203 was retrieved from the Gene Expression Omnibus (GEO) database to screen the differentially expressed genes (DEGs) of S. aureus strains that were treated with CT treatment. Gene ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were used to identify the potential target of CT. Data mining on the microarray dataset indicated that pyruvate kinase (PK) might be involved in the antimicrobial activities of CT. The minimum inhibition concentrations (MICs) of CT or vancomycin against the MRSA strain ATCC43300 and seven other clinical strains were determined using the broth dilution method. The effects of CT on the activity of PK were further measured. In vitro tests verified that CT inhibited the growth of an MRSA reference strain and seven other clinical strains. CT hampered the activity of the PK of ATCC43300 and five clinical MRSA strains. CT might hinder bacterial energy metabolism by inhibiting the activity of PK.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34741111 PMCID: PMC8571311 DOI: 10.1038/s41598-021-01121-9
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Screening of DEGs in MRSA induced by CT treatment: (a) volcano plots; and (b) hierarchical cluster analysis (heatmaps) of the common DEGs between CT treated samples and normal controls in GSE 13203. Statistically significant DEGs were defined with p < 0.05 and absolute log2FC > 1.0 as the cutoff threshold.
Top10 up and downregulated genes in DEGs.
| Category | Gene symbol | Description | log2FC | Adjusted |
|---|---|---|---|---|
| Upregulated | psuG | Pseudouridine-5′-phosphate glycosidase | 2.332 | 0.077 |
| cydB | Cytochrome bd-I ubiquinol oxidase subunit II | 2.029 | 0.011 | |
| hrtB | Hemin transport system permease protein | 1.784 | 0.022 | |
| cap5C | Capsular polysaccharide biosynthesis protein Cap5C | 1.780 | 0.063 | |
| pflA | Pyruvate formate-lyase activating enzyme | 1.737 | 0.142 | |
| cydA | Cytochrome bd-I ubiquinol oxidase subunit I | 1.653 | 0.018 | |
| crtQ | Zeta-carotene desaturase | 1.647 | 0.018 | |
| clfA | MSCRAMM family adhesin clumping factor | 1.640 | 0.018 | |
| opuD2 | Glycine betaine transporter 2 | 1.557 | 0.039 | |
| crtM | Dehydrosqualene synthase | 1.534 | 0.022 | |
| psuG | Pseudouridine-5′-phosphate glycosidase | 2.332 | 0.077 | |
| Downregulated | esaB | Type VII secretion protein | –2.607 | 0.011 |
| pyk | Pyruvate kinase | –2.285 | 0.164 | |
| hutH | Histidine ammonia-lyase | –2.268 | 0.022 | |
| isdB | Iron-regulated heme–iron binding protein | –2.106 | 0.025 | |
| isdG | Staphylobilin-forming heme oxygenase | –2.006 | 0.020 | |
| ribD | Bifunctional diaminohydroxyphosphoribosylaminopyrimidine deaminase/5-amino-6-(5-phosphoribosylamino) uracil reductase | –1.981 | 0.574 | |
| gltS | Sodium/glutamate symporter | − 1.975 | 0.015 | |
| nuc | Thermonuclease | − 1.960 | 0.022 | |
| modA | Molybdate ABC transporter substrate-binding protein | − 1.860 | 0.057 |
FC fold change.
Specimen and tests information on MRSA strains.
| Strains | Source | Date of isolation (month and year) | Antibiotic resistances | Antibiotic sensitivity | V MIC (μg/mL) | CT MIC (μg/mL) |
|---|---|---|---|---|---|---|
| MRSA01 | Sputum | 04/2017 | P, L, E, O, CIP, M, T, CL | G, TI, LINE, RI, V, TMP/SXT | 0.45 | 0.9 |
| MRSA02 | Blood | 04/2017 | P, L, E, O, G, CIP, M, T, CL | TMP/SXT, TI, RI, LINE, V | 0.9 | 0.9 |
| MRSA03 | Sputum | 05/2017 | P, G, L, E, O, CIP, M, T, CL | V, TMP/SXT, TI, RI, LINE | 0.9 | 0.9 |
| MRSA04 | Sputum | 07/2017 | P, L, E, O, CIP, M, T, CL | TMP/SXT, TI, RI, V, LINE | 1.9 | 1.9 |
| MRSA05 | Blood | 07/2017 | P, L, E, O, CIP, M, T, CL | TMP/SXT, TI, RI, LINE, V | 1.9 | 1.9 |
| MRSA06 | Sputum | 08/2017 | P, L, E, G, O, CIP, M, T, CL | TMP/SXT, TI, RI, LINE, V | 1.9 | 1.9 |
| MRSA07 | Sputum | 08/2017 | P, G, L, E, O, CIP, M, T, CL | TMP/SXT, TI, RI, LINE, V | 0.9 | 3.9 |
| ATCC43300 | BJZY | – | – | – | 0.9 | 1.9 |
P penicillin, L levofloxacin, E erythromycin, O oxacillin, CIP ciprofloxacin, M moxifloxacin, T tetracycline, CI clindamycin, G gentamicin, TI tetracycline, LINE linezolid, RI rifampin, V vancomycin, TMP/SXT trimethoprim–sulfamethoxazole, BJZY Beijing Zhongyuan Company, V MIC MIC of vancomycin to MRSA, CT MIC MIC of CT to MRSA.
Figure 3MIC assay of MRSA strains: (a) MICs of CT to seven MRSA strains isolated from clinical specimens and standard MRSA strain ATCC 43300; and (b) MICs of vancomycin to seven MRSA strains isolated from clinical specimens and standard MRSA strain ATCC 43300.
Figure 4Effect of CT on the activity of PK of eight MRSA strains. #Control group versus 1 × MIC group p < 0.05, *control group versus 2 × MIC group p < 0.05, **:1 × MIC group versus 2 × MIC groups p < 0.05.